First Tracks Biotherapeutics (NASDAQ:TRAX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

Other research analysts have also issued research reports about the company. Wedbush initiated coverage on First Tracks Biotherapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $30.00 price target on the stock. Wells Fargo & Company initiated coverage on shares of First Tracks Biotherapeutics in a report on Monday, June 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Leerink Partners started coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $46.00 price objective for the company. Wall Street Zen upgraded First Tracks Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd. Finally, Barclays assumed coverage on First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $38.25.

First Tracks Biotherapeutics Stock Up 5.0%

First Tracks Biotherapeutics stock opened at $20.77 on Wednesday. First Tracks Biotherapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $26.80. The business’s fifty day moving average is $17.96.